第1章 エグゼクティブサマリー

第2章 乾癬のアンメットニーズ

第3章 特定のアンメットニーズ・新しい治療法

第4章 パイプライン：生物製剤

第5章 パイプライン：経口療法

JAK-STAT標的

ホスホジエステラーゼ4(PDE4)阻害剤

その他の標的

第6章 パイプライン：局所療法

M518101

CT327

DRM02

Xantryl

INCB18424

AN2728

MOL4249

DLX105

第7章 商業的展望

第8章 疾病の概要

第9章 現在の治療選択肢

第10章 PsAの治療ガイドライン

図表

目次

Product Code: TC14022401

Over the last decades, therapeutic options for Plaque Psoriasis (PsO)
and Psoriatic Arthritis (PsA) have expanded considerably and improved
patients' pain, function, and quality of life. Approved biologics fill in a
critical unmet need of limited efficacy of DMARDs; however, as in most cases
one drug does not fit the bill for all the patients. The lack of targeted
immune therapies other than TNF-α inhibitors in Psoriasis signals
opportunities for drug developers to bring agents to market that offer
treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer
launched the first oral Rheumatoid Arthritis (RA) drug -Xeljanz
(tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with
moderately to severely active RA who are inadequate responder or intolerant to
Methotrexate (MTX) at a price almost at par with biologics. In the last
couple of years, the face of healthcare has been changing due to challenges -
quality and its affordability and accessibility to the providers and patients.

We believe there is an ample room for an efficacious affordable therapy to tap
the mild to moderate RA pts population where biologics have not made a dent
and expect few potential launches in 2014-15 (OTEZLA - apremilast, Xeljanz -
tofacitinib) and onwards. In this report, we highlight the novel targets -
oral, injectables, and topical drugs in the pipeline for the treatment of
Psoriasis, compare their clinical trials data, and their commercial potential!